By employing novel Thermosphere™ technology, the Emprint™ ablation system is able to maintain a spherical active heating zone across tissue types and throughout an ablation procedure despite tissue desiccation. In fact, the Emprint™ ablation system has demonstrated improved performance in both an in vivo and ex vivo tissue model in comparison to microwave ablation technology on the market today, and in regard to ablation size and shape.
Combined with precise power delivery from the Emprint™ generator, Thermosphere™ technology creates predictable ablation zones across a wide range of tissue types — giving clinicians the confidence they need to deliver the best possible patient outcomes.
* The Emprint™ ablation system is intended for use in percutaneous, laparoscopic, and intraoperative coagulation (ablation) of soft tissue, including partial or complete ablation of non-resectable liver tumors. The Emprint™ system is not intended for use in cardiac procedures.
* For Prescription Use Only: Prescribers should refer to the Emprint™ Ablation System User Guide and Instructions for Use for contraindications, warnings, precautions, and other important product information.
First case presentation of microwave ablation using the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology guided by ENB using the superDimension™ navigation system.
This study showed that EMPRINTTM with ThermosphereTM Technology produces large and spherical ablation zones and may be used to treat unresectable large liver tumors.
This was the first study to evaluate local recurrence after MWA with Thermosphere™ technology in patients with malignant liver tumors. Local tumor control was achieved at a median 16 months follow-up and results were favorable to those of radiofrequency ablation and other MWA technologies reported in the literature.
This study evaluated local recurrence after microwave thermosphere ablation (MTA) of malignant liver tumors. Results from this study showed that local tumor control rate was achieved in subjects with malignant liver tumors after undergoing MTA with the EmprintTM Ablation System.
This study concluded that EmprintTM Ablation System with ThermosphereTM Technology produces predictable ablation zone shape and sizes, allowing more precise treatment planning, and that the system is effective and safe for treatment of challenging perivascular hepatic tumors.
The objective of this study was to compare the accuracy of the EMPRINTTM system for treatment of hepatocellular carcinoma versus predictions, based on the ablation zone chart provided by the manufacturer.
Imagine if ablation zones were truly predictable. That would be revolutionary – for you and your patients.